PTC Therapeutics (PTCT) EVP sells shares to cover RSU tax withholding

Rhea-AI Filing Summary

PTC Therapeutics executive Golden Lee Scott reported an automatic share sale related to tax withholding. On January 8, 2026, Scott sold 866 shares of PTC Therapeutics common stock at $76.45 per share. After this transaction, Scott beneficially owned 92,428 shares of common stock in direct form.

According to the footnote, the sale was made automatically under an irrevocable "sell to cover" election entered into when the equity awards were granted. The sale was used to satisfy tax withholding obligations tied to the vesting of 3,539 restricted stock units (RSUs) from January 7, 2022 grants that originally totaled 14,155 RSUs. This indicates the transaction was administrative in nature and connected to previously granted equity compensation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Golden Lee Scott

(Last) (First) (Middle)

C/O PTC THERAPEUTICS, INC.

500 WARREN CORPORATE CENTER DRIVE

(Street)

WARREN NJ 07059

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
PTC THERAPEUTICS, INC. [ PTCT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CHIEF MEDICAL OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		S		866(1)	D	$76.45	92,428	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares automatically sold pursuant to irrevocable sell to cover elections entered into upon acceptance of the respective grants to satisfy tax withholding obligations in connection with the vesting of 3,539 RSUs from January 7, 2022 grants totaling 14,155 RSUs.

	/s/ Avraham S. Adler, Attorney-in-Fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in this PTC Therapeutics (PTCT) Form 4 filing?

The reporting person is Golden Lee Scott, who serves as EVP & Chief Medical Officer of PTC Therapeutics, Inc.

How many PTC Therapeutics (PTCT) shares did Golden Lee Scott sell?

Golden Lee Scott reported selling 866 shares of PTC Therapeutics common stock on January 8, 2026.

What was the sale price per share in this PTC Therapeutics insider transaction?

The 866 shares of PTC Therapeutics common stock were sold at a price of $76.45 per share.

How many PTC Therapeutics shares does Golden Lee Scott own after the transaction?

Following the reported sale, Golden Lee Scott beneficially owned 92,428 shares of PTC Therapeutics common stock, held directly.

Was this PTC Therapeutics insider sale a discretionary sale or for tax withholding?

The filing states the 866 shares were automatically sold under an irrevocable sell-to-cover election to satisfy tax withholding obligations related to the vesting of 3,539 RSUs from January 7, 2022 grants totaling 14,155 RSUs.

What type of security is involved in this PTC Therapeutics Form 4?

The transaction involves PTC Therapeutics, Inc. common stock, reported in Table I as a non-derivative security. The RSU vesting referenced in the footnote is the underlying equity award that triggered the tax-related sale.